Of these classes, the glycosuricsodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to havebeneficial cardiovascular and renal effects in several clinical trials,independent of diabetes status [10, 11, 12, 13, 14, 15, 16, 17], with proven reductions in HFhospitalizations and cardiovascular death in patients with HFrEF [11, 12]. Here, SLC5A2 is linked to diabetes mellitus.